Article

MEEI gets $11 million

The Massachusetts Eye and Ear Infirmary (MEEI) has received an $11 million grant from the National Institute of Allergy and Infectious Disease, the largest National Institutes of Health grant in the hospital?s 187-year history, to coordinate the Harvard-wide Project on Antibiotic Resistance.

Boston-The Massachusetts Eye and Ear Infirmary (MEEI) has received an $11 million grant from the National Institute of Allergy and Infectious Disease, the largest National Institutes of Health grant in the hospital’s 187-year history, to coordinate the Harvard-wide Project on Antibiotic Resistance.

The goal of the project, led by Michael S. Gilmore, PhD, the Sir William Osler Professor of Ophthalmology at the institution, is to develop new antibiotics to treat highly resistant infections caused by Staphylococcus aureus and other related bacteria. Dr. Gilmore is a part of the Howe Laboratory of Ophthalmology at MEEI.

“Infections from multidrug-resistant bacteria are leading complications of surgeries, from cataract extractions to knee replacements. Understanding how resistance develops in these strains will help guide the judicious and effective use of antibiotics and the development of new treatments that will benefit patients and reduce health care spending,” said Joan W. Miller, MD, the Henry Willard Williams Professor of Ophthalmology, chief of ophthalmology at MEEI and Massachusetts General Hospital, chairwoman of ophthalmology at Harvard Medical School, and an associate medical editor for Ophthalmology Times.

Since 2005, drug-resistant S aureus has killed more people in the United States than HIV/AIDS, and it has become a leading public health concern. Among hospitalized patients, staphylococcal infection is the largest infectious disease problem, and its prevention is a top concern.

Dr. Gilmore recruited a team of investigators from across the Harvard University landscape and from the industry to develop new drugs to treat these infections. He said he hopes the 5-year project will generate 5 to 10 compounds.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.